Just Because Things Are Not Different, Does Not Mean They Are the Same:Biomarker Patterns in Acute Respiratory Distress Syndrome by Shankar-Hari, Manu & Rubenfeld, Gordon D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1097/CCM.0000000000002672
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Shankar-Hari, M., & Rubenfeld, G. D. (2017). Just Because Things Are Not Different, Does Not Mean They Are
the Same: Biomarker Patterns in Acute Respiratory Distress Syndrome. Critical Care Medicine, 45(11), 1955-
1957. https://doi.org/10.1097/CCM.0000000000002672
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Just because things aren’t different, doesn’t mean they are the same: 
biomarker patterns in ARDS 
Manu Shankar-Hari PhD MSc1,2, Gordon D Rubenfeld MD MSc3* 
1Guy's and St Thomas' NHS Foundation Trust, ICU support Offices, 1st Floor, East 
Wing, St Thomas' Hospital, SE1 7EH, UK; 2Division of Infection, Immunity and 
Inflammation, Kings College London, SE1 9RT; 3Interdepartmental Division of 
Critical Care Medicine, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, 
D5 03, Toronto, Ontario, M4N 3M5 
*Corresponding author and reprints 
Gordon D. Rubenfeld, MD MSc FRCPC 
Professor of Medicine 
Interdepartmental Division of Critical Care Medicine, University of Toronto 
Chief, Program in Trauma, Emergency and Critical Care, Sunnybrook Health 
Sciences Center 
2075 Bayview Avenue, Room D108c 
Toronto, ON M4N 3M5 
TEL: 416-480-6100 x2895 
FAX: 416-480-4999   
Financial support: None 
Acknowledgements 
Manu Shankar-Hari is supported by the UK National Institute for Health Research 
Clinician Scientist Award (NIHR-CS-2016-16-011). The views expressed in this 
publication are those of the author(s) and not necessarily those of the National 
Health Service, the National Institute for Health Research, or the United Kingdom 
Department of Health. 
Key words: ARDS, biomarkers, equivalence, biological equivalence 
Word count: Abstract = not applicable 
Main article = 1454 words.  
References = 15 
COI declaration:  No COI to report for this publication. 
Is an inferior wall myocardial infarction the same disease as an anterior wall 
myocardial infarction?  Is breast cancer the same disease as ovarian cancer?   
These are fundamental questions whose answers require insights in to the 
pathophysiology of the disease and the efficacy of different therapies.  These are 
questions whose answers change over time, for example, as our understanding of 
cancer has advanced from morphologic sameness to cell replication mechanism 
sameness, some breast cancers are, in important ways, the same as some ovarian 
cancers(1).  Acute respiratory distress syndrome (ARDS) is a common problem in 
critically ill patients, representing 10% of all ICU admissions and nearly 25% of 
patients requiring mechanical ventilation(2). Biologically, ARDS is characterised as 
acute lung inflammation, associated with increased pulmonary vascular permeability, 
increased lung weight and acute loss of aerated lung tissue(3). Clinically, ARDS is, 
as it has been at least since 1967, a syndrome of acute hypoxemic respiratory failure 
with bilateral pulmonary infiltrates that cannot be attributed solely to heart failure and 
usually occurs in the setting of injury or infection(4).    
The question posed by García-de-Acilu, et al, in this issue of CCM is: Is 
ARDS managed with high flow nasal cannula oxygen (HFNC) the same as ARDS 
managed with endotracheal ventilation?(5)   This question has limited implications 
for clinicians as it does not address the question of the efficacy of HFNC in 
managing ARDS and there are no unique pharmacologic therapies to offer patients 
on HFNC if we decide they have ARDS.  It is primarily of interest to researchers who 
may want support to enrol patients on HFNC in trials of therapy for ARDS and 
mechanistic studies of the syndrome.  The question arises because patients on 
HFNC and other forms of supplemental oxygen are caught in a loophole in the most 
recent attempt to formalize the definition of ARDS which requires a PaO2/FiO2 < 300 
on a PEEP or CPAP of at least 5 cm water(4).  Because of variability in measuring 
the FiO2 and the delivered PEEP on HFNC (6), as well as the potential differences in 
the chest radiograph due to delivered tidal volume and respiratory rate, it is possible 
that some patients classified as having ARDS on HFNC might not meet these criteria 
if they had been intubated.   Note, we specifically say “might not meet these criteria” 
instead of “might not have ARDS” as the developers of the Berlin Definition explicitly 
note that we don’t have a laboratory test for “having ARDS”(4). 
One approach is to simply argue that the method by which a physician 
chooses to deliver oxygen cannot change the underlying mechanism of what she is 
treating.  HFNC may select a group of patients with less severe ARDS if the 
delivered FiO2 and PEEP are both lower than estimated, but there is no reason to 
suspect these patients have a different mechanism causing their acute hypoxemic 
respiratory failure assuming they meet other diagnostic criteria.  Those persuaded by 
this theoretical argument will find the paper by García-de-Acilu M et al superfluous 
and its findings intuitive.  However, providing an empiric answer to the question of 
whether HFNC-ARDS is the same as intubated-ARDS is interesting, if for no other 
reason, because it requires us to address two fundamental issues: one biologic and 
the other statistical.   
In ARDS, the immune responses that lead to the structural and functional 
disruption of the alveolar endothelial and epithelial barrier are well described(3). 
Briefly, leukocytes sense presence of pathogens by detecting pathogen associated 
molecular patterns (PAMPs) such as lipopolysaccharide and tissue damage 
associated molecular patterns (DAMPs) such as mitochondrial nucleic acids with 
pattern recognition receptors, to generate a multitude of immune activation 
mediators through inflammasome and signalosome complexes (3, 7). Thus, the 
alveolar barrier disruption is the final common pathway resulting from a number of 
host responses that are not unique to ARDS, as similar host responses are seen in 
sepsis and trauma (3, 8, 9).  
Blood provides an accessible window to measure and evaluate biomarkers, 
which are indicators of normal biologic processes, pathogenic processes, or 
pharmacologic responses to therapeutic interventions. Recently, Terpstra et al 
reported a systematic review that categorized biomarkers into those associated with 
either ARDS diagnosis or risk of death once ARDS is diagnosed (10). The diagnostic 
markers with strongest association were biomarkers of epithelial dysfunction such as 
Krebs von den Lungen-6 (KL-6), soluble receptor for advanced glycation end 
products (RAGE) and endothelial dysfunction such as von Willebrand factor (vWF). 
The ARDS prognosis markers in this study were markers of either inflammation 
(interleukins IL-4, IL-2, IL-1beta), or endothelial dysfunction (angiopoietin-2) or 
epithelial dysfunction (KL-6) (10). Even though some of the associations are strong, 
the diagnostic or prognostic performance of individual biomarkers is poor and there 
is considerable overlap between ARDS and at-risk populations(11).  There are no 
accepted cut-offs for a biomarker or panel of biomarkers that accurately separate 
ARDS from non-ARDS hypoxemic respiratory failure. There has been some 
progress in using panels of clinical variables combined with biomarkers to identify 
endotypes of ARDS (12).   
In addition to figuring out what biologic measures convincingly identify 
patients with ARDS, there are also two interesting statistical concerns in this study.  
Patients receiving HFNC might be different than other patients with ARDS for 
reasons that have nothing to do with the mechanism of their ARDS.  These 
confounding variables likely relate to the reasons that physicians might choose to 
manage certain patients without intubation.  It isn’t surprising that patients managed 
with HFNC tended to have lower severity of illness as measured by SOFA and 
APACHE II and a different ARDS risk factor distribution, however, it also wouldn't be 
surprising that a difference in biomarkers in these patients might reflect these factors 
as much as any aspect of the mechanism for lung injury.  Therefore, the approach 
taken by García-de-Acilu et al, to match on a propensity score, simply a technique to 
allow near matching on multiple confounding variables, was wise.   
We use statistical hypothesis testing to account for the role of chance in 
scientific studies. Our standard procedure for this, the P value, tells us how unlikely 
the results of the study are if the null hypothesis of equivalence is true.  The problem 
is, the research question in this study is proving the null hypothesis; and while small 
datasets can make equivalence unlikely, no amount of observed data can prove 
equivalence.  It is well known that concluding equivalence from a non-statistically 
significant result is an error, an error of Type II.  If it were not an error, equivalence 
studies would be easy, one would simply perform small under-powered experiments 
that will yield high P values.  Nevertheless, questions of equivalence and non-
inferiority are important and frequently addressed in clinical trials.  These analyses 
require a crucial piece of information that is lacking in this ARDS equivalence study. 
When trialists seek to demonstrate that a new therapy is equivalent or at least 
non-inferior to a standard therapy they must decide how much of a difference doesn’t 
matter.  In the SYNERGY trial of enoxaparin versus unfractionated heparin for non-
ST segment elevation acute coronary syndromes(13), investigators pre-specified 
that as long as enoxaparin did not increase the composite outcome of all-cause 
death or nonfatal myocardial infarction by more than 10% they would conclude that 
enoxaparin was non-inferior to heparin.  That means that if heparin was actually 
better by a 5% improvement in outcome, they would still conclude that enoxaparin 
was no worse.  They could have decided 10% was too big a difference to miss and 
used 5% and would have needed a larger sample size.  There are guidelines for 
selecting clinically persuasive and scientifically justified non-inferiority and 
equivalence margins, but they are debated and subject to interpretation(14). 
How big a difference in biomarkers doesn’t matter? The important information 
in the García-de-Acilu study is not in the Figure 1 boxplots and P values comparing 
HFNC-ARDS with intubated-ARDS; it is in the third column of Table-3.  This table 
tells us how big the differences were in the biomarkers and, more importantly, how 
big a difference could have been missed in this study.   For RAGE, on average, 
patients with HFNC-ARDS had levels that were 280.56 pg/ml lower than matched 
patients who were intubated, but the data were consistent with patients having levels 
that were 969.41 pg/ml lower.  In the largest study addressing the question, the 
difference in RAGE levels in ARDS patients compared to at-risk controls was 1093 
pg/ml; a difference that arguably would have been missed in this study(15).  If a 
difference of 969.41 pg/ml in RAGE, and the extremes of the confidence intervals 
around other biomarkers in Table 3, are inconsequential, then this study provides 
some convincing statistical support for the claim of similarity.  If we actually don’t 
even know what constitutes an important difference in biomarkers, then the empiric 
claim for similarity is problematic. 
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